Precision for Medicine’s Chad Clark, President, and Scott Marshall, Managing Director of Biomarker and IVD Analytics, contribute a new commentary for Bioscience Technology Online on the challenges of biomarker data management. (more…)
In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. (more…)
In a new commentary for PharmExec.com, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. (more…)
In the current supplemental issue of Journal of Managed Care & Specialty Pharmacy (JMCP), Precision’s Jeremy Schafer, Dominic Galante, and Jason Shafrin share results of a recent survey of payers discerning payers’ use of value tools in healthcare decision-making.
Precision for Value’s Larry Blandford offers a new commentary in STAT First Opinion, insisting that payers and the pharmaceutical industry come together to develop a value-based drug reimbursement system. He suggests taking a page from the playbook developed for electronic prescribing as the key to moving forward.
Precision’s David Parker, PhD, senior vice president, diagnostics solutions, recently spoke with Clinical OMICs Editor-in-Chief Chris Anderson about some of the issues inherent in CDx development relationships.
Jeremy Schafer and Maureen Hennessey promote antimicrobial stewardship in a new commentary for Managed Healthcare Executive, offering 4 specific steps: rewarding antimicrobial stewardship, leveraging quality scores, implementing appropriate controls, and the establishment of patient education campaigns.
In the latest edition of Life Science Leader, Precision Oncology president Pat Devitt Risse contributes a new guest column: “Bet On Biomarkers for Better Outcomes.” In the article, Pat advocates for greater use of biomarkers used to accurately pinpoint the patient population that will benefit from a drug during clinical trials.
Precision for Value’s Kelly Wilder is interviewed by PharmaVoice and provides her perspectives on the payer landscape, the definition of value, and best practices for pharmaceutical companies.
Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.